Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCPX

Scorpius Holdings Inc.

Jul 17 • 03:59PM ET

4.20

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-280.10	Insider Own	4.53%	Shs Outstand	0.49M	Perf Week	-0.47%
Market Cap	2.08M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.47M	Perf Month	-72.48%
Income	-36.85M	PEG	-	EPS next Q	-	Inst Own	2.32%	Short Float	0.70%	Perf Quarter	-86.75%
Sales	9.74M	P/S	0.21	EPS this Y	-	Inst Trans	-9.83%	Short Ratio	0.04	Perf Half Y	-94.62%
Book/sh	158.75	P/B	0.03	EPS next Y	-	ROA	-48.71%	Short Interest	0.00M	Perf Year	-97.02%
Cash/sh	3.40	P/C	1.24	EPS next 5Y	-	ROE	-76.41%	52W Range	3.00 - 147.00	Perf YTD	-95.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.72%	ROI	-90.33%	52W High	-97.14%	Beta	-0.17
Dividend TTM	-	Quick Ratio	0.26	Sales past 5Y	325.62%	Gross Margin	-21.20%	52W Low	40.00%	ATR (14)	2.17
Dividend Ex-Date	-	Current Ratio	0.38	EPS Y/Y TTM	25.12%	Oper. Margin	-380.10%	RSI (14)	31.84	Volatility	24.97% 35.33%
Employees	84	Debt/Eq	0.55	Sales Y/Y TTM	40.46%	Profit Margin	-378.23%	Recom	1.00	Target Price	1600.00
Option/Short	No / Yes	LT Debt/Eq	0.43	EPS Q/Q	68.15%	Payout	-	Rel Volume	0.00	Prev Close	4.20
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	358.80%	Earnings	May 29 BMO	Avg Volume	80.47K	Price	4.20
SMA20	-25.64%	SMA50	-74.69%	SMA200	-92.10%	Trades		Volume	0	Change	0.00%

Jul-24-24 08:30AM	Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter (GlobeNewswire)
Jul-18-24 08:30AM	Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility (GlobeNewswire)
Jul-17-24 04:30PM	Scorpius Holdings Announces Reverse Stock Split (GlobeNewswire) -26.17%
Jun-17-24 08:00AM	Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal (GlobeNewswire) -63.30%
Jun-03-24 08:00AM	Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing (GlobeNewswire) +6.13%
07:00AM	Loading…
May-29-24 07:00AM	Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024 (GlobeNewswire) +7.60%
May-20-24 08:00AM	Scorpius Holdings Announces Major Expansion in San Antonio with New State-of-the-Art Storage and Testing Facility (GlobeNewswire) +54.59%
May-16-24 04:15PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire) +28.83%
08:00AM	Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing (GlobeNewswire)
May-15-24 08:00AM	Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing (GlobeNewswire)
May-14-24 01:55PM	Top Midday Decliners (MT Newswires) -57.69%
07:15AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire)
May-07-24 08:30AM	Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald (GlobeNewswire) -5.33%
Apr-29-24 08:00AM	Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023 (GlobeNewswire) +24.26%
Apr-23-24 05:27AM	Scorpius Holdings Gets Non-Compliance Notice From NYSE American (MT Newswires)
05:00PM	Loading…
Apr-22-24 05:00PM	Scorpius Holdings Announces Receipt of Filing Delinquency Notification (GlobeNewswire)
Mar-19-24 08:30AM	Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University (GlobeNewswire)
Mar-14-24 08:30AM	Scorpius Holdings Accepted as a Member of the US Governments BioMaP-Consortium (GlobeNewswire)
Mar-12-24 05:00PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire)
Mar-08-24 12:20AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire) -51.47%
Mar-07-24 04:18PM	Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +8.59%
08:30AM	Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 (GlobeNewswire)
Feb-06-24 08:00AM	NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under SCPX Effective at the Market Open Today (GlobeNewswire) -7.71%
Feb-01-24 08:00AM	NightHawks Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer (GlobeNewswire)
Jan-30-24 08:00AM	NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note (GlobeNewswire)
Jan-25-24 08:30AM	NightHawks Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program (GlobeNewswire) +10.54%
Jan-16-24 08:30AM	NightHawks Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client (GlobeNewswire)
Jan-08-24 08:30AM	NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO (GlobeNewswire)
Jan-03-24 08:30AM	NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University (GlobeNewswire)
Dec-21-23 08:30AM	NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University (GlobeNewswire) +12.30%
08:30AM	Loading…
Dec-18-23 08:30AM	NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company (GlobeNewswire) +18.22%
Dec-12-23 08:30AM	NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets (GlobeNewswire)
Nov-20-23 04:05PM	NightHawk Biosciences Provides Q3 2023 Business Update (GlobeNewswire) -8.68%
Oct-09-23 08:26AM	NHWK: 2Q:23 Results (Zacks) -5.89%
Aug-24-23 08:24AM	Morrisville CEO wants to acquire his company's subsidiary for $45M+ (American City Business Journals)
08:24AM	Morrisville CEO pitches to buy his company's subsidiary for $45M+ (American City Business Journals)
Aug-14-23 04:05PM	NightHawk Biosciences Provides Q2 2023 Business Update (GlobeNewswire)
May-19-23 10:46AM	NHWK: First Scorpius Revenues (Zacks Small Cap Research)
May-15-23 04:05PM	NightHawk Biosciences Provides Q1 2023 Business Update (GlobeNewswire)
Apr-11-23 08:23AM	NHWK: ANTHIM Sales Boost Revenues (Zacks Small Cap Research) -6.10%
Mar-31-23 04:05PM	NightHawk Biosciences Provides 2022 Year End Business Update (GlobeNewswire)
Dec-12-22 09:02AM	NHWK: Shifting Focus to Biomanufacturing (Zacks Small Cap Research)
Nov-14-22 04:01PM	NightHawk Biosciences Provides Third Quarter 2022 Business Update (GlobeNewswire)
Oct-21-22 08:00AM	Nighthawk Biosciences Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility (GlobeNewswire)
Aug-23-22 07:30AM	NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory (GlobeNewswire) -14.57%
Aug-17-22 10:55AM	NHWK: Scorpion Grand Opening 3Q:22 (Zacks Small Cap Research)
10:55AM	NHWK: BLA Filing for ALS Treatment Upcoming (Zacks Small Cap Research)
Aug-10-22 04:05PM	NightHawk Biosciences Provides Second Quarter 2022 Business Update (GlobeNewswire) -6.45%
Jun-13-22 08:00AM	NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services (GlobeNewswire) -6.18%
May-18-22 12:48PM	NHWK: Name Change and New Facility (Zacks Small Cap Research) -7.35%
May-16-22 04:44PM	NightHawk Biosciences Provides First Quarter 2022 Business Update (GlobeNewswire) +14.51% +10.86%
May-10-22 08:00AM	NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35 (GlobeNewswire) -8.29%

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCPX

Scorpius Holdings Inc.

Upgrade your FINVIZ experience